"A dearth of genome-wide association studies focused on non-European populations, plus issues related to applying polygenic risk scores in populations with multiple ancestries, has spurred researchers to design new methods and tools to address these questions."
Illumina and MyOme announced a collaboration and investment by Illumina to advance MyOme's roadmap, including a trial examining whether whole-genome use improves patient outcomes and reduces costs.
"A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes and 10 other common diseases—presaging a day when parents could select children with a greater chance of living a healthier life."
Initiative to Empower the Underserved Community of Patients and Providers with Access to Personal Health Risks and Actionable Information to Prevent or Treat Disease
MyOme delivers actionable genomic insights from whole-genome sequencing, helping patients and providers make personalized lifestyle, prevention, and treatment decisions.
